Genmab A/S August 8, 2024 Copenhagen, Denmark; Interim report for the first six months to 30 June 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), giving Genmab worldwide rights to three candidates in clinical development, including Rinatabart Sesutecan (Rina-S), as well as ProfoundBio’s novel antibody-drug conjugate technology platforms The US Food and Drug Administration (FDA) […]